Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 1;10(12):4568-4584.
eCollection 2020.

Humanized mouse model: a review on preclinical applications for cancer immunotherapy

Ling Yin  1 , Xue-Jing Wang  1 , De-Xi Chen  2 , Xiao-Ni Liu  2 , Xiao-Jun Wang  1
Affiliations
Review

Humanized mouse model: a review on preclinical applications for cancer immunotherapy

Ling Yin et al. Am J Cancer Res. .

Abstract

Due to the refractory and partial sensitive treatments to malignant cancers, immunotherapy has increasingly become a hotspot in effective anti-tumor research. However, at present, existing animal models could not accurately describe the interaction between human tissue and tumor cells for preclinical trials. Furthermore, it is a tough obstacle to reconstitute the immune system and microenvironment in a mouse model identical to humans due to species differences. In the establishment of the humanized mouse model, the co-transplantation of human immunocytes with/without tissues and tumor cells is the key breakthrough to solve this problem. The compelling progress has been investigated in the preclinical drug test for diverse tumor types. This review mainly summarized the development of immunodeficient mice, and the construction and practicability of the humanized mouse model. Furthermore, the investigators also highlight the pros and cons, and recent progress in immunotherapy research for advanced utility of human cancer diseases.

Keywords: Immunodeficient mice; cancer; humanized mouse model; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Advances in immunodeficient mice strain.
Figure 2
Figure 2
Establishment of the humanized immune mouse model.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1. - PMC - PubMed
    1. Aravalli RN, Steer CJ. Immune-mediated therapies for liver cancer. Genes (Basel) 2017;8:76. - PMC - PubMed
    1. Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;125:3335–3337. - PMC - PubMed
    1. Kakimi K, Karasaki T, Matsushita H, Sugie T. Advances in personalized cancer immunotherapy. Breast Cancer. 2017;24:16–24. - PubMed
    1. Wege AK, Ernst W, Eckl J, Frankenberger B, Vollmann-Zwerenz A, Mannel DN, Ortmann O, Kroemer A, Brockhoff G. Humanized tumor mice--a new model to study and manipulate the immune response in advanced cancer therapy. Int J Cancer. 2011;129:2194–2206. - PubMed

LinkOut - more resources